Report of Foreign Issuer (6-k)
November 07 2018 - 7:25AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2018
Commission File Number:
001-31368
SANOFI
(Translation of
registrants name into English)
54, rue La
Boétie, 75008 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F
or Form
40-F.
Form
20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by
Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is
submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule
12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If Yes marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b):
82-
In November 2018, Sanofi issued the press releases attached hereto as Exhibit 99.1 and 99.2 which are
incorporated herein by reference.
Exhibit List
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press release dated November 6, 2018: FDA grants priority review for Dupixent
®
(dupilumab) as potential treatment for adolescents with uncontrolled
moderate-to-severe
atopic dermatitis
|
|
|
Exhibit 99.2
|
|
Press release dated November 1, 2018: Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases
|
2
Exhibit Index
|
|
|
Exhibit No.
|
|
Description
|
|
|
Exhibit 99.1
|
|
Press release dated November 6, 2018: FDA grants priority review for Dupixent
®
(dupilumab) as potential treatment for adolescents with uncontrolled
moderate-to-severe
atopic dermatitis
|
|
|
Exhibit 99.2
|
|
Press release dated November 1, 2018: Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases
|
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
Dated: November 7, 2018
|
|
|
|
|
|
SANOFI
|
|
|
|
|
|
By
|
|
/s/ Alexandra
Roger
|
|
|
|
|
Name:
|
|
Alexandra Roger
|
|
|
|
|
Title:
|
|
Head of Securities Law and Capital Markets
|
4
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (PK) (USOTC:SNYNF)
Historical Stock Chart
From Apr 2023 to Apr 2024